Drug reference

Naratriptan

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 524

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

Treatment of acute migraine ▶BY MOUTH ▶Adult: 2.5 mg, followed by 2.5 mg after at least 4 hours if required, to be taken only if migraine recurs (patient not responding to initial dose should not take second dose for same attack); maximum 5 mg per day Menstrual migraine prophylaxis ▶BY MOUTH ▶Adult: 2.5 mg twice daily, to be taken from 2 days before until 3 days after bleeding starts l UNLICENSED USE g Naratriptan is used for menstrual migraine prophylaxis, h but is not licensed for this indication. Not licensed for use in elderly.

PDF page 524

Contra Indications

Coronary vasospasm. ischaemic heart disease. moderate or severe hypertension. peripheral vascular disease. previous cerebrovascular accident. previous myocardial infarction. previous transient ischaemic attack. Prinzmetal’s angina. uncontrolled hypertension

PDF page 524

Cautions

Conditions which predispose to coronary artery disease. elderly

PDF page 524

Allergy And Cross Sensitivity

Caution in patients with sensitivity to sulfonamides.

PDF page 524

Safety

Interactions

→Appendix 1: naratriptan

PDF page 524

Side Effects

▶Common or very common Dizziness. drowsiness. fatigue. feeling hot. malaise. nausea. paraesthesia. vomiting ▶Uncommon Arrhythmias. feeling abnormal. pain. palpitations. visual impairment ▶Rare or very rare Angina pectoris. colitis ischaemic. coronary vasospasm. face oedema. myocardial infarction. peripheral vascular disease. skin reactions SIDE-EFFECTS, FURTHER INFORMATION Discontinue if symptoms of heat, heaviness, pressure or tightness (including throat and chest) occur.

PDF page 524

Pregnancy

There is limited experience of using 5HT1- receptor agonists during pregnancy; manufacturers advise that they should be avoided unless the potential beneﬁt outweighs the risk.

PDF page 524

Breast Feeding

Withhold breast-feeding for 24 hours.

PDF page 524

Hepatic Impairment

Manufacturer advises caution in mild to moderate impairment (risk of decreased clearance); avoid in severe impairment. Dose adjustments Manufacturer advises maximum 2.5 mg in 24 hours in mild to moderate impairment.

PDF page 524

Renal Impairment

Avoid if eGFR less than 15 mL/minute/1.73 m2. Dose adjustments Max. 2.5 mg in 24 hours.

PDF page 524

Dose and formulations

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Tablet CAUTIONARY AND ADVISORY LABELS 3 ▶Naratriptan (Non-proprietary) Naratriptan (as Naratriptan hydrochloride) 2.5 mg Naratriptan 2.5mg tablets | 6 tablet P £24.55 DT = £4.25 | 12 tablet P £8.68–£46.00 ▶Naramig (GlaxoSmithKline UK Ltd) Naratriptan (as Naratriptan hydrochloride) 2.5 mg Naramig 2.5mg tablets | 6 tablet P £24.55 DT = £4.25

PDF page 524

Clinical care

Patient And Carer Advice

Driving and skilled tasks Drowsiness may affect performance of skilled tasks (e.g. driving).

PDF page 524

Dose text by age group

Adult

2.5 mg, followed by 2.5 mg after at least 4 hours

First-line fragment. Read the complete Indications and Dose section above.

PDF page 524

Adult

2.5 mg twice daily, to be taken from 2 days

First-line fragment. Read the complete Indications and Dose section above.

PDF page 524

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

Naratriptan

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 524

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

PDF page 524

Contra Indications

PDF page 524

Cautions

Conditions which predispose to coronary artery disease. elderly

PDF page 524

Allergy And Cross Sensitivity

Caution in patients with sensitivity to sulfonamides.

PDF page 524

Safety

Interactions

→Appendix 1: naratriptan

PDF page 524

Side Effects

PDF page 524

Pregnancy

There is limited experience of using 5HT1- receptor agonists during pregnancy; manufacturers advise that they should be avoided unless the potential beneﬁt outweighs the risk.

PDF page 524

Breast Feeding

Withhold breast-feeding for 24 hours.

PDF page 524

Hepatic Impairment

PDF page 524

Renal Impairment

Avoid if eGFR less than 15 mL/minute/1.73 m2. Dose adjustments Max. 2.5 mg in 24 hours.

PDF page 524

Dose and formulations

Medicinal Forms

PDF page 524

Clinical care

Patient And Carer Advice

Driving and skilled tasks Drowsiness may affect performance of skilled tasks (e.g. driving).

PDF page 524

Dose text by age group

Adult

2.5 mg, followed by 2.5 mg after at least 4 hours

First-line fragment. Read the complete Indications and Dose section above.

PDF page 524

Adult

2.5 mg twice daily, to be taken from 2 days

First-line fragment. Read the complete Indications and Dose section above.

PDF page 524

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.